Imugene Limited announced VAXINIA test progressed to combination cohort & Monotherapy Cohort 3

Imugene Limited (ASX: IMU) reported that cohort 2 of both the intravenous (IV) and intratumoral (IT) arms of the monotherapy trial had been cleared, allowing it to open cohort 1 of the combination study (with Pembrolizumab) and cohort 3 for both arms of the monotherapy dose escalation. The new cancer-killing virus CF33- hNIS was being tested as part of the Phase 1 Metastatic Advanced Solid Tumours (MAST) research.

Patients with metastatic or advanced solid tumours who had undergone at minimum two lines of normal treatment therapy prior to enrolment in the multicentre Phase 1 MAST trial received a modest dosage of VAXINIA as the study's first treatment.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com